The results of 2 phase 2b trials suggest sutezolid and delpazolid could provide safer alternatives to linezolid in shorter drug regimens for drug-resistant TB.
In total, 55% of active tuberculosis, 99% of latent tuberculosis, 61% of hepatitis B, 35% of HIV, and 83% of hepatitis C infections were new diagnoses.
The 25% reduction in the price of pretomanid could save Global Drug Facility clients upwards of $3 million a year.
The battery-powered device is the first to detect Mycobacterium tuberculosis in saliva in addition to blood and sputum.
Other trends included worrisome rises in tuberculosis, measles, and pertussis.
In the wake of US funding cuts, the WHO is urging global health leaders, donors, and policymakers to protect and maintain TB support and care services.
Malaria, HIV, and TB programs are already feeling impacts from the cuts, with scale-backs also depleting healthcare services in Afghanistan.
The trial is evaluating the safety and efficacy of MTBVAC, a single shot, live-attenuated TB vaccine, in people with latent TB in 3 countries.
Of children aged 5 to 10 years, about 40% had abnormal lung function post-treatment, rising to 65% in older children.
In a study in Belarus and Uzbekistan, 96% of patients with drug-resistant TB who received the regimens had successful treatment outcomes.
